ROBINUL FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROBINUL FORTE (ROBINUL FORTE).
Glycopyrrolate is a quaternary ammonium anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors (M1, M2, M3) at postganglionic parasympathetic effector sites, reducing gastrointestinal motility, salivary secretion, and gastric acid secretion.
| Metabolism | Minimal hepatic metabolism; primarily excreted unchanged in urine and bile. |
| Excretion | Renal (approx. 50-70% unchanged) and biliary/fecal (approx. 30-50% as unchanged drug and metabolites). |
| Half-life | Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or renally impaired patients, requiring dose adjustment. |
| Protein binding | Low protein binding, approximately 15-25%, primarily to albumin. |
| Volume of Distribution | Approximately 1-2 L/kg, indicating extensive extravascular distribution (e.g., tissues including GI tract). |
| Bioavailability | Oral: 10-25% (variable due to first-pass metabolism); IM: near-complete (approximately 100% relative to IV). |
| Onset of Action | Oral: 30-60 minutes; IM: 15-30 minutes; IV: 2-5 minutes. |
| Duration of Action | Oral: 4-6 hours; IM: 4-6 hours; IV: 2-4 hours. Anticholinergic effects may persist longer, especially in GI motility inhibition. |
| Molecular Weight | 326.4 Da (as glycopyrrolate) |
1-2 mg orally twice daily; may be increased to 1-2 mg three times daily if needed. Maximum dose: 4 mg daily.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in children under 12 years; for children 12 years and older, same dosing as adults. |
| Geriatric use | Initiate at lower dose (1 mg once or twice daily) due to increased anticholinergic sensitivity; monitor for cognitive impairment and urinary retention. |
| 1st trimester | Limited human data; animal studies show no evidence of teratogenicity. Use only if clearly needed. |
| 2nd trimester | Consider risk-benefit; may cause fetal tachycardia. |
| 3rd trimester | May cause neonatal anticholinergic effects (e.g., ileus, tachycardia). Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for ROBINUL FORTE (ROBINUL FORTE).
| Placental transfer | Crosses placenta (low molecular weight, quaternary amine structure limits transfer; animal studies show fetal exposure) |
| Breastfeeding | Excreted in breast milk in small amounts; unlikely to affect infant but monitor for anticholinergic effects. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
GlaucomaObstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy)Gastrointestinal obstructive disease (e.g., pyloric stenosis)Paralytic ileusMyasthenia gravis (unless for anticholinesterase reversal)Severe ulcerative colitisToxic megacolonKnown hypersensitivity to glycopyrrolate
| Precautions | May cause heat prostration due to inhibition of sweating in high ambient temperatures, Caution in patients with glaucoma (narrow-angle), pyloric obstruction, prostatic hypertrophy, or urinary retention, May cause drowsiness or blurred vision; caution when driving or operating machinery, Use with caution in patients with coronary artery disease, congestive heart failure, arrhythmias, or hypertension, May decrease gastric motility in patients with gastric stasis |
| Food/Dietary | Take on an empty stomach to maximize absorption. Avoid high-fat meals as they may decrease absorption. Limit alcohol intake as it can exacerbate dizziness and drowsiness. Grapefruit juice may increase glycopyrrolate levels; avoid concurrent use. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | Glycopyrrolate (ROBINUL FORTE) is a quaternary ammonium anticholinergic with minimal placental transfer. Animal studies show no teratogenicity at clinically relevant doses. First trimester: Limited human data, but theoretical low risk due to poor placental penetration. Second/third trimester: No known fetal malformations; may cause transient fetal tachycardia or decreased GI motility if high doses used. Overall, classified as FDA Pregnancy Category B (pre-2015) and generally considered low risk. |
| Fetal Monitoring | Maternal: Monitor heart rate and blood pressure for anticholinergic effects; in high doses, assess for urinary retention or constipation. Fetal/neonatal: No specific monitoring required with standard doses; if used near term, observe neonate for transient tachycardia or meconium ileus (rare). |
| Fertility Effects | No adverse effects on fertility reported in animal or human studies. Anticholinergic effects do not impact ovulation or spermatogenesis at therapeutic doses. |
| Clinical Pearls | Glycopyrrolate is a quaternary ammonium anticholinergic that does not cross the blood-brain barrier, thus minimal CNS effects. It is preferred in patients with cognitive concerns. Onset of action is ~1 hour; titrate dose at 1-2 week intervals. May reduce gastric motility and cause constipation; monitor for ileus. Use with caution in glaucoma, myasthenia gravis, and GI obstruction. Avoid in patients with toxic megacolon. |
| Patient Advice | Take this medication on an empty stomach, 1 hour before meals or at least 2 hours after meals. · Avoid activities requiring mental alertness if dizziness or blurred vision occurs. · Drink plenty of fluids to prevent constipation, but avoid hot beverages which can increase side effects. · Do not crush or chew extended-release tablets; swallow whole. · Report any difficulty urinating, severe constipation, or eye pain immediately. |